Revenue Performance - Total revenues for the three months ended March 31, 2025, were approximately $2.3 million, a decrease of $104 thousand or 4% compared to $2.4 million for the same period in 2024[138]. - In-person experience revenues increased by approximately $402 thousand, or 32%, to approximately $1.7 million for the three months ended March 31, 2025, driven by higher revenue from arena events[139]. - Casual mobile gaming revenue decreased by approximately $506 thousand, or 45%, to $618 thousand for the three months ended March 31, 2025, primarily due to market contraction and increased competition[140]. Expenses - General and administrative expenses increased by approximately $2.6 million, or 92%, to approximately $5.5 million for the three months ended March 31, 2025, largely due to increased legal and professional fees[144]. - Research and development expenses were $181 thousand for the three months ended March 31, 2025, a slight decrease from $195 thousand for the same period in 2024[143]. - In-person costs (exclusive of depreciation and amortization) increased by approximately $225 thousand, or 35%, to approximately $861 thousand for the three months ended March 31, 2025, due to costs associated with third-party events[141]. - Casual mobile gaming costs (exclusive of depreciation and amortization) decreased to $582 thousand for the three months ended March 31, 2025, down from $937 thousand for the same period in 2024, reflecting reduced user acquisition costs[142]. Net Loss and Income - The company reported a net loss of $4.9 million for the three months ended March 31, 2025, compared to a net loss of $1.8 million for the same period in 2024, reflecting a deterioration of $3.1 million[138]. - Other income (expense), net, improved by $37 thousand, resulting in approximately $24 thousand of other income for the three months ended March 31, 2025, compared to $13 thousand of other expense for the same period in 2024[146]. - The company realized a gain of $367 thousand on investment in a money market fund for the three months ended March 31, 2025, with no such investments reported for the same period in 2024[147]. - The company recognized a loss of $0.3 million on investments in marketable securities for the three months ended March 31, 2025, compared to no investments in the same period of 2024[148]. - The loss on foreign currency transactions was approximately $0.6 million for the three months ended March 31, 2025, compared to $0 for the same period in 2024[150]. - The decrease in the fair value of digital assets was approximately $63 thousand for the three months ended March 31, 2025, with no decrease reported for the same period in 2024[151]. - Interest income, net, was approximately $864 thousand for the three months ended March 31, 2025, compared to approximately $859 thousand for the same period in 2024[152]. Cash Flow and Assets - Current assets increased to approximately $98.0 million as of March 31, 2025, from $94.7 million as of December 31, 2024[153]. - Working capital surplus decreased to approximately $57.3 million as of March 31, 2025, from $64.3 million as of December 31, 2024[153]. - Net cash used in operating activities was approximately $2.2 million for the three months ended March 31, 2025, compared to $2.1 million for the same period in 2024[157]. - Net cash used in investing activities was approximately $45.1 million for the three months ended March 31, 2025, compared to $14.5 million for the same period in 2024[158][159]. - Net cash provided by financing activities was approximately $7.5 million for the three months ended March 31, 2025, compared to approximately $7.6 million for the same period in 2024[160][161]. - Cash and cash equivalents were approximately $19.5 million as of March 31, 2025, not including $49.2 million of short-term investments[154].

Financial Performance - Net revenues for the three months ended May 31, 2025, decreased by $2.9 million, or 29.0%, to $7.1 million compared to $10.0 million for the same period in 2024[93]. - Gross margin for the PaperPie segment decreased by $2.2 million, or 37.9%, to $3.6 million for the three months ended May 31, 2025, with gross margin as a percentage of net revenues dropping to 59.3% from 65.3%[99]. - Operating income for the PaperPie segment decreased by $0.3 million, or 37.5%, to $0.5 million during the three months ended May 31, 2025[101]. - Net revenues for the Publishing segment decreased by $0.1 million, or 9.1%, to $1.0 million during the three-month period ended May 31, 2025[103]. - Gross margin for the Publishing segment decreased by $0.1 million, or 16.7%, to $0.5 million during the three-month period ended May 31, 2025[104]. Operating Expenses - Total operating expenses for the PaperPie segment decreased by $1.9 million, or 38.0%, to $3.1 million during the three-month period ended May 31, 2025[100]. - Total operating expenses for the Publishing segment decreased by $0.1 million, or 25.0%, to $0.3 million during the three-month period ended May 31, 2025[105]. Active Brand Partners - The average number of active Brand Partners decreased by 5,700, or 42.5%, to 7,700 during the three months ended May 31, 2025, from 13,400 in the same period a year ago[98]. - Approximately 15.4% of active Brand Partners maintained consignment inventory, totaling $1.2 million at May 31, 2025[134]. Cash Flow and Debt Management - The Company experienced positive cash inflows from operations of $1,396,500 during the first three months of fiscal year 2026[107]. - As of the end of the first fiscal quarter of 2026, the revolving bank credit facility loan balance was $4.2 million with $0.6 million in available capacity[106]. - The Company plans to reduce debt by selling the Hilti Complex, with proceeds expected to pay off Term Loans and the Revolving Loan[123]. Loan Agreements and Amendments - The Company executed the Second Amendment to the Loan Agreement, waiving the fixed charge ratio default and reducing the revolving commitment from $15 million to $14 million, effective May 10, 2023[112]. - The Third Amendment extended the Revolving Loan maturity date to January 31, 2024, and introduced a stepdown to the Revolving Commitment from $13.5 million to $4 million by January 31, 2024[113]. - The Fourth Amendment increased the Revolving Loan commitment to $8 million and extended the maturity date to May 31, 2024, while allowing additional purchase orders up to $2.1 million[115]. - The effective interest rate on the Revolving Loan was 10.31% at May 31, 2025, with a borrowing rate of SOFR + 6.00%[121]. Inventory Valuation - The Company has estimated a valuation allowance for both current and noncurrent inventory of $1.2 million as of May 31, 2025[135]. - Noncurrent inventory balances prior to valuation allowances were $17.6 million at May 31, 2025, with valuation allowances of $0.8 million[133]. - The Company has an allowance for credit losses estimated at $0.1 million for both May 31, 2025, and February 28, 2025[131]. Management Plans - Management's plans include reducing inventory to generate free cash flows and building the active PaperPie Brand Partners to pre-pandemic levels[123].

AVTX-009 and HS Market - AVTX-009, an anti-IL-1β mAb, is a lead compound with potential for best-in-class and best-in-disease profile in hidradenitis suppurativa (HS)[7] - The HS market is expected to grow to over $10 billion by 2035[8] - Avalo is enrolling patients in a Phase 2 LOTUS trial for HS, with topline data expected in mid-2026[8] - AVTX-009 has 15x higher affinity than lutikizumab, potentially predictive of higher efficacy and less frequent dosing[10] Financials and Strategy - Avalo expects its cash runway to extend into 2028[8] - As of March 31, 2025, Avalo had approximately $125 million in cash[70] - As of March 31, 2025, Avalo's adjusted market capitalization was $284.5 million, based on an adjusted common share count of 35.5 million and a stock price of $8.01[70] IL-1β and AVTX-009 Advantages - IL-1β gene expression is up to 100x increased in HS lesions compared to healthy skin[26] - AVTX-009 is designed to target the inflammatory driver of Hidradenitis Suppurativa (HS) to address significant unmet need[15] - AVTX-009 has a subcutaneous bioavailability of 73% and a half-life of 19 days[35]

Bezuclastinib Clinical Programs - Bezuclastinib combined with sunitinib demonstrated a 12-month median Progression-Free Survival (mPFS) in heavily pre-treated Gastrointestinal Stromal Tumors (GIST) patients[10] - In the APEX study, initial data in Advanced Systemic Mastocytosis (AdvSM) patients shows promising clinical activity with Bezuclastinib[10] - In Apex study, the Overall Response Rate (ORR) of CR + CRh + PR + CI was 73% (8 out of 11 patients) per CRRC assessment in TKI therapy-naïve AdvSM patients[27] - In Apex study, 88% of patients achieved a ≥ 50% reduction in serum tryptase levels[35] - In Apex study, 100% of patients with at least 2 cycles of treatment achieved a ≥ 50% reduction in bone marrow mast cell burden[35] - In Apex study, 92% of patients with at least 2 cycles of treatment achieved a ≥ 50% reduction in KIT D816V VAF[35] Market Opportunity - The global Total Addressable Market (TAM) potential for Bezuclastinib exceeds $3.5 billion, including $1.5 billion for NonAdvSM, $700 million for 2nd-line GIST, and $300 million for AdvSM[14] - Approximately 90% of Systemic Mastocytosis (SM) patients present with non-advanced systemic mastocytosis (NonAdvSM)[18] - Approximately 10% of patients present with advanced systemic mastocytosis (AdvSM)[18] Pipeline and Financials - The company's research pipeline includes novel, small-molecule targeted therapies for rare diseases, including an FGFR1-sparing, pan-mutant FGFR2 and a CNS-penetrant ErbB2[7] - The company's cash runway is expected to fund operations into 2025, with $289.1 million in cash as of September 30, 2022[7, 83]

Financial Results Announcement - Educational Development Corporation announced its fiscal 2026 first quarter financial results on July 7, 2025[5] - A press release detailing the financial results is included as Exhibit 99.1[7] Earnings Call - The earnings call for fiscal 2026 is scheduled for July 7, 2025, at 3:30 PM CT (4:30 PM ET)[6]

Financial Performance and Goals - Evolus aims to achieve over 20% non-GAAP operating income with at least $700 million in revenue by 2028[10] - The company is targeting $700 million in global sales by 2028, representing a 28% CAGR from 2023[20] - Evolus expects to launch Evolysse and gain approval within the next 12 months[10] - The company's revenue guidance for 2024 is between $260 million and $270 million[21] Market and Product Expansion - The total addressable market for injectables is projected to reach $10 billion by 2028[20] - Evolus plans to expand internationally to achieve $100 million in international revenue by 2028[23] - The company has filed for filler approval with a launch planned in the second half of 2025[23] Clinical Study Results - In a Phase III study, Jeuveau demonstrated non-inferiority to Botox, with responder rates of 87.2% for Jeuveau and 82.8% for Botox at day 30[38] - A post-hoc analysis of a Phase III clinical study showed comparable results between Jeuveau and Botox in improving glabellar line scale and subject satisfaction[44, 48] Evolysse Dermal Fillers - US NLF pivotal study results for Evolysse Form vs Restylane-L showed non-inferiority at 6 months[120] - US NLF pivotal study results for Evolysse Smooth vs Restylane-L also met the primary endpoint of non-inferiority at 6 months[128]

Investor Presentation Second Quarter 2022 Safe Harbor The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the company undertakes no obli ...

expl WORLD HOLDINGS, INC. Investor Presentation Third Quarter 2022 Safe Harbor 2 The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Such forward-looking statements speak only as of the date hereof, and the ...

Q4 & FULL-YEAR 2022 FINANCIAL RESULTS VIRTUAL FIRESIDE CHAT FEBRUARY 28, 2023 slido.com event code: #EXPI Forward Looking Statements There will be a number of forward-looking statements made today that should be considered in conjunction with the cautionary statements contained in the Company's SEC filings. Forward-looking statements are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Please see our filings with the SEC, including ou ...

Market Opportunity & Disease Burden - Heart failure affects over 6 million people in the U S [9], leading to over 1 1 million hospital discharges and over 1 3 million emergency room visits annually [11] - The annual costs associated with heart failure are expected to reach $70 billion by 2030 in the U S [11] - The U S annual net addressable market for Barostim is estimated at $2 2 billion, assuming an average selling price (ASP) of $29,000 [37] Barostim Therapy & Clinical Evidence - Barostim is presented as a neuromodulation therapy designed to improve heart failure symptoms [8] - Barostim implantation is a 60-minute procedure with a 97% freedom from major complications [46, 48] - Real-world evidence demonstrates an 85% relative reduction in hospital visits per year post-Barostim implant (average 1 92 years) compared to pre-implant (12 months) [67] Financial Performance & Guidance - Worldwide revenue for 2024 was $51 3 million, representing 31% growth [87, 88] - The gross margin for 2024 was 84% [87, 88] - The company's revenue guidance for full year 2025 is $55 0 – $58 0 million, with a gross margin of 83% – 84% and operating expenses of $95 0 – $98 0 million [90]